Association between polymorphism of tumor necrosis factor-alpha promoter and response to lamivudine treatment in patients with chronic hepatitis B.

1 1034

Cited 0 times in

Cited 5 times in

Authors: Yong Kwang Park ; Jung Min Lee ; Do Young Kim ; Hye Young Chang ; Ja Kyung Kim ; Chun Kyon Lee ; Jun Yong Park ; Sang Hoon Ahn ; Kwan Sik Lee ; Kwang Hyub Han

MeSH: Adult ; Analysis of Variance ; Case-Control Studies ; Confidence Intervals ; Disease Progression ; Female ; Follow-Up Studies ; Gene Expression Regulation ; Genotype ; Hepatitis B, Chronic/diagnosis ; Hepatitis B, Chronic/drug therapy* ; Hepatitis B, Chronic/genetics* ; Humans ; Lamivudine/therapeutic use* ; Liver Function Tests ; Male ; Middle Aged ; Multivariate Analysis ; Odds Ratio ; Polymorphism, Genetic* ; Probability ; Promoter Regions, Genetic/drug effects* ; Reference Values ; Risk Assessment ; Severity of Illness Index ; Treatment Failure ; Treatment Outcome ; Tumor Necrosis Factor-alpha/genetics* ; Tumor Necrosis Factor-alpha/metabolism ; Young Adult

Keywords: Hepatitis B virus ; Lamivudine ; Tumor necrosis factor-alpha ; Single nucleotide polymorphism

Abstract: BACKGROUND: TNF-alpha promoter polymorphism is known to play an important role in the immunopathogenesis of infection of hepatitis B virus.

AIMS: We investigated whether polymorphisms of TNF-alpha promoter at position -308 or -238 had associations with the response to lamivudine treatment.

METHODS: A total of 89 healthy subjects (control group) and 225 patients with chronic hepatitis B treated with lamivudine were included in this study. Polymorphisms of TNF-alpha promoter at position -308 and -238 were analyzed by polymerase chain reaction. Recruited patients were classified according to the outcome of lamivudine treatment into the responder (103 patients) or non-responder (122 patients) group.

RESULTS: The numbers of A allelic polymorphism of TNF-alpha promoter at position -238 were four (2.2%) in the control, five (2.4%) in the responder and 19 (7.8%) in the non-responder group. The A allele was noted significantly more frequently in the responder than non-responder group (P = 0.012). At position -308, a significant difference was observed between the control group (14; 7.9%) and total chronic hepatitis B patients (15; 3.3%) (P = 0.015).

CONCLUSIONS: Our study demonstrated that the non-response to lamivudine treatment in patients with chronic hepatitis B might be related to the A allelic polymorphism of TNF-alpha promoter at position -238.

Appears in Collections:: 1. College of Medicine (의과대학) > Yonsei Biomedical Research Center (연세의생명연구원) > 1. Journal Papers
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers

Yonsei Authors: Kim, Do Young(김도영)
Kim, Ja Kyung(김자경) https://orcid.org/0000-0001-5025-6846
Park, Yong Kwang(박용광)
Park, Jun Yong(박준용) https://orcid.org/0000-0001-6324-2224
Ahn, Sang Hoon(안상훈) https://orcid.org/0000-0002-3629-4624
Lee, Kwan Sik(이관식) https://orcid.org/0000-0002-3672-1198
Lee, Jung Min(이중민)
Chang, Hye Young(장혜영)
Han, Kwang-Hyub(한광협) https://orcid.org/0000-0003-3960-6539

Show full item record Find it @ YMLIB

YUHSpace: Association between polymorphism of tumor necrosis factor-alpha promoter and response to lamivudine treatment in patients with chronic hepatitis B.